A conversation with Nancy Flournoy
From MaRDI portal
Publication:254418
DOI10.1214/14-STS495zbMath1332.01059arXiv1504.03089WikidataQ56675501 ScholiaQ56675501MaRDI QIDQ254418
Publication date: 8 March 2016
Published in: Statistical Science (Search for Journal in Brave)
Full work available at URL: https://arxiv.org/abs/1504.03089
Related Items (1)
Cites Work
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Information in a two-stage adaptive optimal design
- A note on the robustness of the continual reassessment method
- The treatment versus experimentation dilemma in dose finding studies
- Asymptotics in response-adaptive designs generated by a two-color, randomly reinforced urn
- Optimal properties of the Bechhofer-Kulkarni Bernoulli selection procedure
- Iterated least squares in multiperiod control
- Operating characteristics of the standard phase I clinical trial design.
- Asymptotic normality of maximum likelihood estimators from multiparameter response-driven designs
- Investigating therapies of potentially great benefit: ECMO. With comments and a rejoinder by the author
- Design and Analysis of Phase I Clinical Trials
- Stage‐Wise Adaptive Designs
- Efficient group sequential tests with unpredictable group sizes
- The Randomized Play-the-Winner Rule in Medical Trials
- A Random Walk Rule for Phase I Clinical Trials
- Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
- Women in Statistics: Scientific Contributions Versus Rewards
This page was built for publication: A conversation with Nancy Flournoy
